Intensity Therapeutics Shares Dive 25% After 1-for-25 Reverse Split Effective Feb. 18
Intensity Therapeutics announced a 1-for-25 reverse stock split effective Feb. 18, 2026, reducing outstanding shares from 63.3 million to 2.5 million and aiming to regain Nasdaq compliance. Shares plunged over 25% Friday, trading near 52-week lows and more than 30% below their 50-day SMA despite broader market gains.
1. Reverse Split Announcement
Intensity Therapeutics approved a 1-for-25 reverse stock split that takes effect at 4:01 p.m. ET on Feb. 18, 2026, with post-split trading beginning Feb. 19. The split will reduce the number of outstanding shares from approximately 63.3 million to about 2.5 million to meet Nasdaq’s minimum bid price requirement.
2. Market Reaction
Shares fell more than 25% on the announcement day, closing around $0.27 and nearing a 52-week low of $0.18. This decline occurred despite a 1.47% gain in the Technology sector, indicating company-specific selling pressure.
3. Technical Analysis
The stock is trading 30.8% below its 20-day simple moving average and 36.1% below its 50-day SMA, reflecting significant short-term weakness. The RSI stands at 46.41 (neutral territory) while the MACD remains above its signal line, suggesting mixed momentum.
4. Outlook and Catalysts
The next key catalyst is the March 12, 2026 earnings release, with analysts forecasting an EPS loss of $0.05 versus a loss of $0.22 a year ago and no revenue. This report could further influence the stock’s compliance status and investor sentiment.